Skip to main navigation
Skip to search
Skip to main content
Scholars @ UT Health San Antonio Home
Help & FAQ
English
Español
Home
Profiles
Research units
Publications
Datasets
Search by expertise, name or affiliation
Voreloxin. DNA-intercalating drug topoisomerase II inhibitor oncolytic
H. Moualla
, D. A. Mills
,
R. Hromas
, C. F. Verschraegen
Research output
:
Contribution to journal
›
Review article
›
peer-review
3
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Voreloxin. DNA-intercalating drug topoisomerase II inhibitor oncolytic'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Pharmacology, Toxicology and Pharmaceutical Science
Vosaroxin
100%
DNA
50%
Acute Myeloid Leukemia
50%
Toxicity
25%
Neutropenia
25%
Monotherapy
25%
Platinum
25%
Ovary Cancer
25%
Cytotoxic Agent
25%
Drug
25%
Hematologic Malignancy
25%
Intercalating Agent
25%
DNA Topoisomerase (ATP Hydrolysing)
25%
Naphthyridine Derivative
25%
Gyrase Inhibitor
25%
Cell Cycle
25%
Apoptosis
25%